A battery startup making silicon anode cells (batteries that store more energy per unit weight than conventional graphite cells but face durability and manufacturing challenges) and a coronary device company building a scaffold designed to support an artery and later allow natural vessel motion share nothing obvious: different customers, different buyers, different regulatory pathways, different supply chains. One sells to automaker procurement teams evaluating cell chemistry over multi-year validation cycles. The other needs interventional cardiologists, hospital purchasing committees, the FDA, and payers to accept a new device category. The technical evidence each has produced is real. The audiences who will decide their commercial fate cannot read that evidence in its native form.
Both companies are doing the same thing with the gap between what they've proven and what they need the market to believe. And the thing they're doing determines whether an Anchor publication creates dependency or ends up competing with a marketing hire.
The Conversion
Coreshell announced commercial-format 60 Ah cells built with domestically sourced metallurgical silicon in December 2024. That is a manufacturing milestone. The same announcement frames it as "A Pathway to Mass-Market EV Adoption." By March 2025, a $24 million funding round described "leading automakers" testing Coreshell anodes with "promising results," but named none. By June 2026, the blog has shifted to geopolitical framing: "China Controls the Battery Supply Chain. Here's How America Breaks Free." The IEA independently confirms the supply-chain concentration problem (top three graphite refining countries held 99% share in 2024). But the strategic relevance of a problem is not evidence that Coreshell has solved it commercially. No named automaker has publicly confirmed receiving or advancing Coreshell cells past the A-sample stage (early validation hardware, not a purchase commitment).
Elixir's BIOADAPTOR trial reported 0.5% cardiac death versus 3.7% for the comparator stent at four years in a 445-patient randomized study. Those numbers are favorable. They are also company-presented, from a trial sized for regulatory submission rather than clinical practice change. The DynamX device holds CE Mark approval in Europe but remains investigational in the United States. European commercial traction, meaning physician adoption, hospital purchasing, payer acceptance, is unquantified in any accessible source. Between "favorable trial readout" and "practice-changing device" sit FDA premarket approval, physician adoption, hospital purchasing decisions, and payer acceptance. Each gate has its own evidentiary bar. None are publicly cleared.
In both cases, the mechanism is the same. A company produces evidence valid within a specific technical or clinical register: cycle-life data, trial endpoints. The audiences who matter most cannot evaluate that evidence in its native register. A procurement officer doesn't read battery degradation curves. A hospital purchasing committee doesn't interpret target lesion failure rates (the percentage of patients who experience cardiac death, heart attack at the treated vessel, or need for repeat intervention). So the evidence gets translated into the buyer's language. And translation performed under commercial pressure drifts toward the audience's preferred conclusion.
The previously named evidence-to-adoption gap describes the structural distance between proof and purchase. What I'm naming here is what companies do to make that distance appear shorter than it is.
This is confidence laundering. The term borrows from financial laundering, but the analogy needs precision. In financial laundering, the purpose is to obscure the origin of funds. In confidence laundering, the purpose is to obscure the constraints on evidence: the caveats, sample sizes, regulatory gates, and validation steps that bound what a milestone actually proves. The input is legitimate. The output appears validated. The conversion in between strips the conditions under which the evidence holds, producing claims that look cleaner than the underlying proof warrants.
Where the Laundering Happens
If confidence laundering were visible only in companies with long regulatory cycles and slow-moving evidence, it would tell us something about regulated industries and nothing about Anchor. Two other portfolio customers test whether the mechanism is structural.
TinyFish is the most instructive case because the company does the calibration work and then undoes it at the organizational boundary. The WebVoyager benchmark post explicitly states the benchmark "does not measure latency, cost efficiency, or how well an agent handles tasks outside the 15-site set." The Vault credential-isolation post lists four categories of security risk it doesn't address. The fetch-quality evaluation discloses that 45 URLs is a small sample and that TinyFish has "an obvious interest in the outcome." These are honest, well-bounded technical documents. But the homepage says "89.9% Mind2Web accuracy" and "built to complete production tasks accurately at scale" without those constraints. The engineering blog holds the line. The front door launders through it.
The location of the conversion matters for Anchor. At Coreshell and Elixir, the laundering runs through the company's own press releases and blog, the same channel an Anchor publication would occupy. At TinyFish, the engineering content is already calibrated; the laundering happens downstream, at the boundary between technical documentation and commercial positioning. An Anchor publication sitting alongside TinyFish's engineering blog would duplicate work the company already does well. An Anchor publication that held the homepage claims accountable to the blog's own stated limitations would occupy a position no one inside the company has an incentive to fill.
Okta tests the pattern through a third mechanism: partnership announcements. The Google Cloud integration for AI agent identity governance is described as "coming soon," with a forward-looking disclaimer noting features "may not be delivered or obtained on time or at all." The Anthropic integration for Claude Enterprise is a beta. These are real commercial relationships. They are not evidence that enterprise agent governance is deployed or working. Okta's own survey finds 90% of executives confident in their AI visibility while 52% of employees admit using AI tools without approval. A CSA/Aembit survey found 68% of organizations cannot distinguish agent activity from human activity and only 22% apply access frameworks consistently to AI agents. The partnership press releases describe a capability arriving. The survey data describes a problem persisting. The laundering here operates through announcement cadence itself: each new partnership implicitly signals that the previous one delivered value, when the public evidence shows the underlying governance gap hasn't closed.
Shade Tree Fund is the floor case. Climate philanthropy operates through private donor relationships and grantmaking deliberation that leave almost no public trace. Whether Shade Tree faces confidence laundering pressure is invisible from outside. This marks the structural limit of public-signal analysis.
Where Dependency Forms and Breaks
Every company in the portfolio faces pressure from investors, customers, and partners to speak in the register of solved problems while operating in the register of promising evidence. The pattern describes a structural condition, and no one is exempt from it. Whether Anchor's position makes it capable of resisting that pressure depends on three features of its structural situation. It is external: no equity stake, no board seat, no commercial interest in the customer's deal pipeline. It publishes on a cadence rather than on demand: a scheduled publication doesn't respond to the sales team's need for a claim by Friday. And it operates across domains: a platform that also serves coronary devices and identity security has no incentive to adopt any single customer's preferred narrative frame.
These conditions make it possible for an Anchor publication to maintain the distinction between "we built 60 Ah cells with domestic silicon" and "automakers are adopting our technology." The customer's internal team faces direct incentives to close that gap narratively. An external publication that preserves it is doing work the customer cannot easily replicate, because the pressure to launder comes from inside the organization.
But the dependency breaks if the customer treats the Anchor publication as raw material for its own conversion. If a marketing team takes Anchor's calibrated language, strips the constraints, and publishes the cleaned version on its own channels, Anchor becomes an upstream input to the laundering process. The publication would remain accurate and become irrelevant simultaneously, because the conversion happens downstream of Anchor's output. This is the TinyFish pattern in reverse: honest content that gets laundered at the organizational boundary.
The Decision
This reframes customer targeting. The highest-value Anchor deployments are where the milestone-to-market gap is widest, the buyer cannot evaluate the original evidence directly, and the credibility cost of overclaiming is highest: regulated industries, long technical sales cycles, sophisticated evaluators who will eventually audit the claim. It also reframes sales positioning. "We help you tell your story" is a pitch that competes with every content agency and every competent marketing hire. "We help you say precisely what you've proven, so your buyer doesn't discover later that you overclaimed" is a pitch with almost no competition, because no one inside the company has the structural incentive to make it.
Whether any Anchor publication currently in production is performing the conversion rather than preventing it. If the publications are helping customers launder confidence, the pattern names a problem Anchor is creating, one that undermines the value proposition before it can be sold.
Moderate confidence. The pattern is visible across four customers with distinct mechanisms, which makes it structural rather than coincidental. The limitation is direct: I cannot see the Anchor publications themselves or their effect on customer workflows. The diagnosis rests entirely on the public gap between what each company has proven and what its narrative claims. Whether Anchor sits on the right side of that gap is a question only the founders can answer by reading their own output.
- TinyFish's own caveats: The WebVoyager benchmark post is unusually transparent about what its 91.1% accuracy result does and doesn't measure, making it a useful reference point for what calibrated technical communication looks like before it reaches the homepage.
- Okta's executive-employee perception gap: Okta's AI Agents at Work 2026 survey found 65% of executives said AI usage policies were "very clear" while only 43% of knowledge workers agreed, a split that illustrates how confidence laundering can operate inside an organization, not just outward.
- OWASP's vendor-neutral risk frame: The Non-Human Identities Top 10 provides an independent taxonomy of agent identity risks including improper offboarding, overprivileged access, and long-lived secrets, useful for testing whether Okta's product announcements address practitioner concerns or category-creation language.
- Coreshell's narrative drift: Coreshell's blog has shifted from cell-level technical milestones in late 2024 to geopolitical supply-chain framing by mid-2026, a trajectory worth tracking as a live example of confidence laundering in motion if automaker validation signals remain absent.